08:00 , Feb 20, 2001 |  BC Week In Review  |  Clinical News

Amiscan: Began Phase II trial

Draxis Health Inc. (DRAX; TSE:DAX), Mississauga, Ontario   Product: Amiscan   Business: Diagnostics/Imaging   Therapeutic category: Imaging agent   Target: NA   Description: Technetium-labeled D-glucaric acid derivative   Indication: Diagnose acute myocardial infarction (AMI)  ...
07:00 , Jul 17, 2000 |  BC Week In Review  |  Clinical News

Amiscan: Began Phase I testing

Draxis Health Inc. (DRAX; TSE:DAX), Mississauga, Ontario   Product: Amiscan   Business: Diagnostics/Imaging   Therapeutic category: Imaging agent   Target: NA   Description: Technetium-labeled D-glucaric acid derivative   Indication: Diagnose acute myocardial infarction (AMI)  ...
07:00 , May 15, 2000 |  BC Week In Review  |  Clinical News

Amiscan: Phase I testing update

Draxis Health Inc. (DRAX; TSE:DAX), Mississauga, Ontario   Product: Amiscan   Business: Diagnostics/Imaging   Therapeutic category: Imaging agent   Target: NA   Description: Technetium-labeled D-glucaric acid derivative   Indication: Diagnose acute myocardial infarction (AMI)  ...
08:00 , Nov 22, 1999 |  BC Week In Review  |  Clinical News

Amiscan: Phase I/II

University of Genoa researchers reported in the Journal of Nuclear Medicine data from 28 patients showing that Amiscan identified and localized AMI both early and accurately. Molecular Targeting Technologies Inc. , Malvern, Penn.   Product:...
08:00 , Nov 15, 1999 |  BC Week In Review  |  Company News

Draxis, Molecular Targeting deal

DRAX’s Draximage Inc. subsidiary (Kirkland, Quebec) received exclusive worldwide rights outside specified countries in southeast Asia to manufacture and sell Molecular Targeting’s Amiscan formulation of 99m Tc-glucarate to diagnose acute myocardial infarction. Molecular Targeting will...
07:00 , Jun 8, 1998 |  BC Week In Review  |  Company News

Draxis, Molecular Targeting deal

Molecular Targeting and DRAXF’s Draximage Inc. subsidiary (Kirkland, Quebec) will develop, manufacture and market imaging agents, the first of which is Amiscan , a formulation of 99m Tc-glucarate to diagnose acute myocardial infarction. Draxis Health...
08:00 , Nov 13, 1995 |  BC Week In Review  |  Clinical News

Molecular Targeting regulatory update

The privately held Malvern, Penn., company received European Patent No. 438,502 covering its Amiscan product to detect acute myocardial infarction (AMI) and stroke. Molecular Targeting said Amiscan has the potential to diagnose AMI very early...